Ascendiant Capital Reiterates Buy Rating on Outlook Therapeutics
Ascendiant Capital maintains its optimistic view on Outlook Therapeutics with a $10 price target, a 762.07% upside from the current price.
Key Points
- Ascendiant Capital reiterated its buy rating on Outlook Therapeutics with a $10 price target on June 11, 2026.
- Ascendiant Capital's $10 price target implies 762.07% upside from Outlook Therapeutics, Inc.'s ($OTLK) current $1.16 share price.
- Outlook Therapeutics, trading near $1.12, has a market cap of $181.3 million and a 52-week high of $3.39.
- Ghiath Sukhtian made significant insider purchases, while analysts maintain mixed outlooks with a mean target of $5.5.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 11, 2026, Ascendiant Capital reiterated its buy rating on Outlook Therapeutics, Inc. (NasdaqCM: OTLK), setting a price target of $10. Analyst Edward Woo maintains confidence in the company's potential, despite its current share price trading around $1.12.
Outlook Therapeutics, Inc. Stock Up 79.9%
Shares of NasdaqCM:OTLK traded near $1.12. Outlook Therapeutics has a market cap of approximately $181.3 million. The stock has experienced a 52-week low of $0.16 and a high of $3.39. With a beta of 0.983, the stock shows moderate volatility. The company's forward P/E ratio is not meaningful as it isn’t profitable, with a negative EPS of -1.13.
Other Institutional Activity in Outlook Therapeutics
Several institutional investors have been active in Outlook Therapeutics. Armistice Capital, LLC holds 4,168,000 shares valued at about $857,774. Vanguard Capital Management LLC has 1,967,160 shares worth approximately $405,235. Geode Capital Management, LLC increased its holdings by 287,142 shares, ending with 603,606 shares valued at $124,235. Gilpin Wealth Management, LLC also added 245,962 shares, holding a total of 600,162 shares valued at $123,514. BlackRock, Inc. upped its stake by 72,929 shares to 477,471 shares, valued at $98,264.
Insider Buying and Selling at Outlook Therapeutics, Inc.
Recent insider activity includes several significant transactions. On June 2, 2026, Yezan Munther Haddadin purchased 29,000 shares at $0.83. Ghiath Sukhtian was notably active on May 28, 2026, buying 8,539,709 shares at $0.59 and selling 12,029,999 shares on the same day. On May 27, 2026, Faisal Ghiath Sukhtian acquired 122,174 shares at $0.41.
Analysts Set New Price Targets
On June 11, 2026, Ascendiant Capital maintained its buy rating on Outlook Therapeutics with a $10 price target. The consensus among analysts is a buy, with a mean price target of $5.5 based on three opinions. Other firms, such as Chardan Capital, have a hold rating with a $1 target, reflecting mixed views on the stock's potential.
About Outlook Therapeutics
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Iselin, New Jersey. It focuses on developing monoclonal antibodies for eye diseases, particularly an ophthalmic formulation of bevacizumab, known as ONS-5010. This product is in Phase-III trials for treating wet age-related macular degeneration. Led by CEO Mr. Robert Charles Jahr, the company collaborates with Cencora and employs 17 people.
Bottom Line
Ascendiant Capital's reaffirmation of its buy rating and $10 price target for Outlook Therapeutics highlights the firm's confidence in the company's prospects. Investors should note that 13F filings and analyst ratings are backward-looking and may not represent current positions or opinions. Tracking these changes can provide insights into institutional sentiment and stock performance expectations.
Get Outlook Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OTLK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.